Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2007

01-03-2007 | Article

Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999–2004

Authors: H.-X. Wu, J. Wu, T. Wong, A. Andonov, Q. Li, K. Dinner, T. Donaldson, S. Paton, Enhanced Hepatitis Strain Surveillance System (c/o Ms. Marlene Huard, Executive Assistant)

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2007

Login to get access

Abstract

The purpose of this study was to compare hepatitis C virus (HCV) incidence and recent patterns of transmission within Aboriginal and non-Aboriginal Canadians. Cases of newly acquired HCV infection (in patients ≥15 years) reported to the Enhanced Hepatitis Strain Surveillance System from six jurisdictions in Canada were analyzed. Information on demographic and clinical characteristics as well as risk factors for HCV infection was collected using standardized questionnaires. Univariate analysis showed Aboriginal patients to be significantly more likely than non-Aboriginal patients to report injection drug use (77.1% vs. 64.0%; p < 0.05), to be female (54.6% vs. 37.6%; p < 0.05), to report high-risk sexual behaviors (48.6% vs. 34.1%, p < 0.05), and to report drug snorting (45.7% vs. 32.7%, p < 0.05). The median age of Aboriginal patients was significantly younger than that of non-Aboriginal patients (31 years [range, 15–71] vs. 34 years [range, 15–81]; p < 0.05). The overall incidence of HCV infection per 100,000 people aged 15 years and older was 18.9 (95% confidence interval [CI] 15.5–23.1) in Aboriginal people and 2.8 (95%CI 2.6–3.1) in non-Aboriginal people. Poisson regression analysis revealed that Aboriginal Canadians were more likely than non-Aboriginal Canadians to develop acute hepatitis C (adjusted rate ratio 5.8, 95%CI 4.7–7.3). An appropriate and effective public health strategy that includes planned and implemented prevention programs in partnership with the Aboriginal community is needed.
Literature
1.
go back to reference Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567PubMedCrossRef Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558–567PubMedCrossRef
2.
go back to reference World Health Organization (1999) Hepatitis C—global prevalence (update). Wkly Epidemiol Rec 74:425–427 World Health Organization (1999) Hepatitis C—global prevalence (update). Wkly Epidemiol Rec 74:425–427
3.
go back to reference Wong T, Lee SS (2006) Hepatitis C: a review for primary care physicians. CMAJ 174:649–659PubMed Wong T, Lee SS (2006) Hepatitis C: a review for primary care physicians. CMAJ 174:649–659PubMed
4.
go back to reference Zou S, Zhang J, Tepper M et al (2001) Enhanced surveillance of acute hepatitis B and C in four regions in Canada, 1998 to 1999. Can J Infect Dis 12:357–363PubMed Zou S, Zhang J, Tepper M et al (2001) Enhanced surveillance of acute hepatitis B and C in four regions in Canada, 1998 to 1999. Can J Infect Dis 12:357–363PubMed
5.
6.
go back to reference Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, Strathdee SA, Currie SL, Schechter MT, O’Shaughnessy MV (2001) Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 165:889–895PubMed Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, Strathdee SA, Currie SL, Schechter MT, O’Shaughnessy MV (2001) Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 165:889–895PubMed
7.
go back to reference Goldberg D, Anderson E (2004) Hepatitis C: who is at risk and how do we identify them? J Viral Hepatitis 11(Suppl 1):12–18CrossRef Goldberg D, Anderson E (2004) Hepatitis C: who is at risk and how do we identify them? J Viral Hepatitis 11(Suppl 1):12–18CrossRef
8.
9.
go back to reference Waldram JB, Herring DA, Young TK (1995) Aboriginal health in Canada: historical, cultural, and epidemiological perspectives. University of Toronto, Toronto, pp 1–9 Waldram JB, Herring DA, Young TK (1995) Aboriginal health in Canada: historical, cultural, and epidemiological perspectives. University of Toronto, Toronto, pp 1–9
10.
go back to reference Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, Heath K, Tyndall MW, O’Shaughnessy MV, Schechter MT (2003) Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 168:19–24PubMed Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, Heath K, Tyndall MW, O’Shaughnessy MV, Schechter MT (2003) Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 168:19–24PubMed
12.
go back to reference Wu HX, Andonov A, Giulivi A, Goedhuis NJ, Baptiste B, Furseth J, Poliquin D, Chan JI, Bolesnikov G, Moffat B, Paton S, Wu J (2005) Enhanced surveillance for childhood hepatitis B virus infection in Canada, 1999–2003. Int J Med Sci 2:143–146PubMed Wu HX, Andonov A, Giulivi A, Goedhuis NJ, Baptiste B, Furseth J, Poliquin D, Chan JI, Bolesnikov G, Moffat B, Paton S, Wu J (2005) Enhanced surveillance for childhood hepatitis B virus infection in Canada, 1999–2003. Int J Med Sci 2:143–146PubMed
13.
go back to reference Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL (1999) Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29:908–914PubMedCrossRef Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL (1999) Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29:908–914PubMedCrossRef
14.
go back to reference Minuk GY, Uhanova J (2003) Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol 17:707–712PubMed Minuk GY, Uhanova J (2003) Viral hepatitis in the Canadian Inuit and First Nations populations. Can J Gastroenterol 17:707–712PubMed
15.
go back to reference Bowker SL, Soskolne CL, Houston SC, Newman SC, Jhangri GS (2004) Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in a northern Alberta population. Can J Public Health 95:188–192PubMed Bowker SL, Soskolne CL, Houston SC, Newman SC, Jhangri GS (2004) Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in a northern Alberta population. Can J Public Health 95:188–192PubMed
16.
go back to reference Howard G, Anderson RT, Russell G, Howard VJ, Burke GL (2000) Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol 10:214–223PubMedCrossRef Howard G, Anderson RT, Russell G, Howard VJ, Burke GL (2000) Race, socioeconomic status, and cause-specific mortality. Ann Epidemiol 10:214–223PubMedCrossRef
17.
go back to reference Nyamathi AM, Christiani A, Windokun F, Jones T, Strehlow A, Shoptaw S (2005) Hepatitis C virus infection, substance use and mental illness among homeless youth: a review. AIDS 19(Suppl 3):34–40CrossRef Nyamathi AM, Christiani A, Windokun F, Jones T, Strehlow A, Shoptaw S (2005) Hepatitis C virus infection, substance use and mental illness among homeless youth: a review. AIDS 19(Suppl 3):34–40CrossRef
18.
go back to reference Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noel L, Tyndall M, Wild C, Mun P, Baliunas D (2005) Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 82:250–266PubMed Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, El-Guebaly N, Noel L, Tyndall M, Wild C, Mun P, Baliunas D (2005) Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 82:250–266PubMed
19.
go back to reference Adelson N (2005) The embodiment of inequity: health disparities in Aboriginal Canada. Can J Public Health 96(Suppl 2):45–61 Adelson N (2005) The embodiment of inequity: health disparities in Aboriginal Canada. Can J Public Health 96(Suppl 2):45–61
20.
go back to reference Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER (2001) Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91:42–46PubMedCrossRef Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER (2001) Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91:42–46PubMedCrossRef
21.
go back to reference Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43:250–256PubMedCrossRef Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group (2006) Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 43:250–256PubMedCrossRef
22.
go back to reference Kamal SM, Fouly AE, Kamel RR Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH (2006) Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130:632–638PubMedCrossRef Kamal SM, Fouly AE, Kamel RR Hockenjos B, Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J, Afdhal NH (2006) Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 130:632–638PubMedCrossRef
Metadata
Title
Incidence and risk factors for newly acquired hepatitis C virus infection among Aboriginal versus non-Aboriginal Canadians in six regions, 1999–2004
Authors
H.-X. Wu
J. Wu
T. Wong
A. Andonov
Q. Li
K. Dinner
T. Donaldson
S. Paton
Enhanced Hepatitis Strain Surveillance System (c/o Ms. Marlene Huard, Executive Assistant)
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0267-7

Other articles of this Issue 3/2007

European Journal of Clinical Microbiology & Infectious Diseases 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.